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Introduction: Pulmonary arterial hypertension is a fatal disease characterized by progressive remodeling of the
pulmonary arteries and an increase in pulmonary vascular resistance. Up to 50% of patients with systemic sclerosis
have pulmonary arterial hypertension, which significantly affects the prognosis. The endothelin receptor antagonist
bosentan is used for the treatment of pulmonary arterial hypertension and shows a great beneficial effect. However,
the most frequent side effect of bosentan is liver toxicity, which often requires dose reduction and discontinuation.
Case presentation: We report two cases (a 64-year-old Japanese woman and a 69-year old Japanese woman) of
systemic sclerosis, both with severe Raynaud’s phenomenon and pulmonary arterial hypertension. Both patients
had initially received bosentan monotherapy, which caused liver toxicity as indicated by increased levels of alanine
aminotransferase, alkaline phosphatase, and gamma-glutamyltransferase. After dose reduction or discontinuation of
bosentan, these liver function abnormalities were normalized and the patients subsequently received retreatment
with a combination of bosentan and ursodeoxycholic acid. The results of liver function tests did not show any
abnormalities after this combination therapy.
Conclusions: These reports suggest the usefulness of ursodeoxycholic acid for preventing liver toxicity caused by
bosentan. Thus, the addition of ursodeoxycholic acid to the treatment protocol is expected to be useful when liver
toxicity emerges as a side effect of bosentan.
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Pulmonary arterial hypertension is a debilitating disease
characterized by progressive remodeling of the pulmon-
ary arteries with proliferation of fibrous tissue in the ves-
sel walls, leading to death caused by right ventricular
failure. Approximately 15 to 50% of patients with sys-
temic sclerosis have pulmonary arterial hypertension,
which significantly affects the prognosis [1,2]. There is
increasing evidence that endothelin-1 plays a pathogenic
role in pulmonary arterial hypertension [3]. Several ran-
domized clinical trials have demonstrated the great efficacy* Correspondence: itot@hirakata.kmu.ac.jp
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unless otherwise stated.of endothelin receptor antagonists in pulmonary arterial
hypertension; thus bosentan, as the first endothelin recep-
tor antagonist to be marketed, was approved for the treat-
ment of pulmonary arterial hypertension in the USA and
Canada in 2001 by the Food and Drug Administration and
in Japan in 2005. Bosentan has been reported to be effective
for pulmonary arterial hypertension, establishing its pos-
ition as a novel treatment [4,5], and has recently been ap-
proved for the prevention of digital ulcers in systemic
sclerosis in Europe.
The most frequent severe side effect of bosentan is
known to be liver toxicity [4-8]. The package insert of
bosentan indicates that the incidence of liver toxicity is
14.3% in Japanese clinical studies and 11% in US clinicalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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surveillance in European clinical studies shows annual
increased transaminase levels of 10.1% in 4623 cases,
with interruption of bosentan administration being re-
quired in 3.2% of cases [7]. In addition, a Phase III
placebo-controlled study for 16 weeks showed 9% liver
toxicity, which is dose-dependent [5]. The therapeutic
options for pulmonary arterial hypertension would be
expanded if we could find a means to limit liver toxicity.
In the presence of liver toxicity, a dose reduction or
discontinuation of bosentan needs to be considered.
Although ursodeoxycholic acid can be efficacious against
liver injury in clinical practice, there are no published re-
ports of its usefulness in combating bosentan-induced
liver toxicity. The incidence of liver toxicity appears to
be decreased when ursodeoxycholic acid is simultan-
eously started with bosentan, but definite evidence of
this efficacy has not previously been established.Figure 1 Clinical course of Case 1. Bosentan monotherapy was started in
appeared. Abnormal results of liver function tests were normalized within
combination therapy of bosentan (62.5mg/day) and ursodeoxycholic acid
results of liver function tests, and the dose of both ursodeoxycholic acid a
March 2011, respectively. No abnormal results of liver function tests were
aminotransferase; GGT, gamma-glutamyltransferase.Two of our patients showed liver toxicity after initial
bosentan monotherapy but not with the subsequent
addition of ursodeoxycholic acid to their treatment
protocol. This is the first report that suggests the use-
fulness of ursodeoxycholic acid combination therapy
to prevent liver toxicity caused by bosentan.
Case presentations
Case 1
A 64-year old Japanese woman who presented with edema
around her fingers and forearm followed by rapid deve-
lopment of skin sclerosis was diagnosed with systemic
sclerosis. She was anti-topoisomerase I (Scl-70) antibody
positive and had 35mmHg of estimated right ventricular
pressure, as shown by echocardiography in 2006. She was
prescribed prednisolone at 7.5mg/day. She was negative for
both hepatitis B surface antigen (HBs Ag) and hepatitis C
virus antibody (HCV Ab). In 2007, dyspnea at exertion andMay 2008 at 125mg/day, and after a month, liver function abnormalities
a month after the discontinuation of bosentan. In February 2009,
(300mg/day) was started. There were no subsequent abnormal
nd bosentan were increased to 600mg/day and 125mg/day from
observed. Abbreviations: ALP, alkaline phosphatase; ALT, alanine
Figure 2 Clinical course of Case 2. Bosentan 125mg/day was
started in July 2011; however, liver function abnormalities appeared
after 3 weeks (August 2011). Bosentan was reduced to 62.5mg/day and
ursodeoxycholic acid (300mg/day) was added simultaneously. Liver
function abnormalities were normalized by September 2011. Bosentan
was increased to the initial dose (125mg/day) concomitantly with
increased ursodeoxycholic acid (600mg/day), and no liver function
abnormalities appeared. Abbreviations: ALP, alkaline phosphatase; ALT,
alanine aminotransferase; GGT, gamma-glutamyltransferase.
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ings of a chest computed tomography scan showed bilateral
pulmonary fibrotic lesion and an elevated KL-6 level of
4360U/mL; she was diagnosed with pulmonary fibrosis. In
addition, echocardiography results showed an elevation of
her estimated right ventricular pressure to 50mmHg; she
was therefore clinically diagnosed with pulmonary arterial
hypertension (World Health Organization, WHO, func-
tional class III) associated with connective tissue disease-
derived pulmonary fibrosis.
After bosentan treatment was initiated in May 2008
at 125mg/day, dyspnea at exertion improved and her
6-minute walking distance was increased by 40m from
332m; however, the results of blood tests indicated liver
function abnormalities: increased levels of alanine ami-
notransferase (ALT; 4.5 times the normal upper limit),
alkaline phosphatase (ALP; 3.2 times the normal upper
limit), and gamma-glutamyltransferase (GGT; 6.4 times
the normal upper limit; Figure 1). No other additional
drugs were administered during the 2 months before
and after the bosentan administration. An ultrasound
examination of her liver revealed no morphologic abnor-
mality. The abnormal levels revealed in the liver function
tests were normalized soon after the discontinuation of
bosentan; however, dyspnea at exertion gradually deterio-
rated, and therefore bosentan 62.5mg/day and ursodeoxy-
cholic acid 300mg/day were started simultaneously from
February 2009. The results of her liver function tests did
not show any abnormalities even after 2 years of the com-
bination therapy, and the dose of both ursodeoxycholic acid
and bosentan were increased to 600mg/day and 125mg/day,
respectively from March 2011. No abnormal levels were
found in the results of her liver function tests during 31
months of follow-up after the dose elevation of bosen-
tan. Bosentan improved her estimated right ventricular
pressure to 35mmHg, subjective symptoms from WHO
functional class III to II, and Raynaud’s phenomenon
after bosentan retreatment, and she is currently receiv-
ing bosentan as an out-patient.
Case 2
A 69-year-old Japanese woman who presented severe
Raynaud’s phenomenon, hardening of the skin on her fin-
gers and joint pain was diagnosed with systemic sclerosis.
She was anti-centromere antibody and anti-mitochondria
antibody positive. Echocardiography results showed
30mmHg of estimated right ventricular pressure in
2008. Betamethasone 0.25mg/day was introduced to
control her joint pain. Raynaud’s phenomenon and
dyspnea at exertion started to deteriorate from April
2011. Imaging findings did not show any abnormality
in her lung field but echocardiography indicated an
elevation of her estimated right ventricular pressure to
45mmHg, and we thus clinically diagnosed pulmonaryarterial hypertension associated with connective tissue
disease (WHO functional class III).
Bosentan 125mg/day was started from July 2011, and
this resulted in the improvement of breathlessness at ex-
ertion; however, after 3 weeks the results of her liver
function tests revealed abnormal levels: elevation of ALT
(1.9 times the normal upper limit), ALP (2.5 times the
normal upper limit), and GGT (3.9 times the normal
upper limit; Figure 2). No additional drugs were admin-
istered during the 2 months before the bosentan admin-
istration, and an ultrasound examination of her liver
showed no morphologic abnormality at this time point.
She was negative for both HBs Ag and HCV Ab. Bosentan
was reduced to 62.5mg/day and ursodeoxycholic acid
was introduced simultaneously at 300mg/day. Her liver
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ation of the combination therapy. Ursodeoxycholic
acid was increased to 600mg/day and bosentan was in-
creased to the initial dose of 125mg/day from October
2011. No abnormalities in her liver function were seen
during 24 months of follow-up. Bosentan improved her
estimated right ventricular pressure to 30mmHg and
her subjective symptoms from WHO functional class
III to II after the introduction of bosentan.
Discussion
The results of the two patients’ liver function tests
after initial bosentan monotherapy were abnormal, but
not when ursodeoxycholic acid was combined as an
adjunctive therapy with bosentan. This finding indi-
cates that ursodeoxycholic acid is effective at prevent-
ing liver toxicity caused by bosentan, at least in the
patients we treated.
Bosentan is mainly metabolized by cytochrome P450
enzymes CYP3A4 and CYP2C9 of the liver [10] but its
pharmacokinetic variability is attributed to liver uptake
transporters as well as metabolic enzymes, and the cause
of liver injury is suggested to be an inhibition of the bile
salt export pump [11]. Since ursodeoxycholic acid has
been reported to induce an increased expression of
CYP3A [12], the useful effect of ursodeoxycholic acid
might be attributable to progression of the CYP3A-
mediated metabolism of bosentan.
Even though a gradual increase in the dosage of bosentan
is recommended, liver toxicity often occurs after its intro-
duction or an increase in the dosage. If severe transaminitis
(an over 8-fold increase in ALT/aspartate aminotransferase,
AST, of the normal upper limit) occurs, bosentan treatment
should be stopped immediately. However, if there is only
mild transaminitis (less than an 8-fold increase in ALT/
AST of the normal upper limit), bosentan can be reintro-
duced after dose reduction or interruption. Abnormal re-
sults of liver function tests are, in most cases, normalized
after discontinuing bosentan, but we are often reluctant to
restart bosentan. Our report suggests that it is, however,
worth trying the reintroduction along with ursodeoxycholic
acid, at least on the transient mild transaminitis. Pulmonary
arterial hypertension still remains an incurable disease
with a severe prognosis, and it is therefore important to
start treatment with specific and effective drugs. Because
bosentan is useful for the treatment of pulmonary arterial
hypertension, it is desirable to avoid a dose reduction or
discontinuation due to liver intolerance. Although there are
alternative drugs (such as another endothelin receptor an-
tagonist, ambrisentan, and phosphodiesterase type 5 inhibi-
tors, sildenafil and tadalafil) with low liver toxicity approved
for pulmonary arterial hypertension [13], it remains prefer-
able to have more options available to us. Ursodeoxycholic
acid is commonly used because of its safety and relativelylow incidence of side effects, and its concomitant adminis-
tration might help control the side effects of bosentan.
Conclusions
In summary, the present report suggests that ursodeoxy-
cholic acid has the potential to repress liver toxicity
caused by bosentan. Thus, the combined use of oral
ursodeoxycholic acid with bosentan is expected to be
useful when liver toxicity emerges as a side effect of
bosentan monotherapy.
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